Matching geography Reports matching your search in: Join Alert Me now! Receive bi-weekly email alerts on new market research Sign up today!
|
Parkinson's Disease: market research reports
A disease of the motor system, generally, PD affects people over the age of 50. Early symptoms of PD are subtle and occur gradually. In some people the disease progresses more quickly than in others. Symptoms of Parkinson’s Disease would be tremor in body or trembling in hands, arms, legs, jaw, and face; rigidity, or stiffness of the limbs and trunk; slowness of movement or impaired balance and coordination. These are very visible symptoms, and patients may have difficulty walking, talking, or completing other simple tasks.
As the disease progresses, the shaking, or tremor, which affects the majority of PD patients may begin to interfere with daily activities. Other symptoms may include depression and other emotional changes; difficulty in swallowing, chewing, and speaking; urinary problems or constipation; skin problems; and sleep disruptions. There are currently no blood or laboratory tests that have been proven to help in diagnosing sporadic PD. Therefore the diagnosis is based on medical history and a neurological examination. The disease can be difficult to diagnose accurately.
There is no cure for PD, but a variety of medications provide dramatic relief from the symptoms. Usually, patients are given levodopa combined with carbidopa. Carbidopa delays the conversion of levodopa into dopamine until it reaches the brain. Anticholinergics may help control tremor and rigidity. Other drugs, such as bromocriptine, pramipexole, and ropinirole, mimic the role of dopamine in the brain, causing the neurons to react as they would to dopamine. An antiviral drug, amantadine, also appears to reduce symptoms.
Parkinson's Disease market research reports and industry analysis
|
|
$3,500.00
|
Parkinson's Disease – Pipeline Review, H1 2013
2/28/2013 | published by: Global Markets Direct
... Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. Parkinson's Disease - Pipeline Review, Half Year is ...
|
read more...
|
$2,000.00
|
Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017
1/16/2013 | published by: MarketsandMarkets
... a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain ...
|
read more...
|
$4,650.00
|
Neurostimulation Devices Market, 2012-2017
11/5/2012 | published by: Banyan Wharf Consultants Ltd.
... mainly focus on spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS) and sacral nerve stimulation (SNS). The market is still niche, with limited number of devices available in the market. The ...
|
read more...
|
$1,699.00
|
|
|
$2,500.00
|
Vaccines 2012-16 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments
9/19/2012 | published by: Kalorama Information
... emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer’s disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attach, Helicobacter pylori infection, multiple sclerosis, Parkinson’s disease, West Nile virus (WNV) ...
|
read more...
|
$1,500.00
|
Analyzing the Global CNS Market
9/1/2012 | published by: Aruvian's R'search
... development. This is largely due to significant levels of unmet medical need and the clinical specificity of many CNS drugs. The CNS disorders market may be segmented into numerous subcategories, including Alzheimer's disease (AD), epilepsy, ...
|
read more...
|
$650.00
|
|
|
$11,400.00
|
|
|
$4,400.00
|
Parkinson's Disease
8/9/2012 | published by: Decision Resources
... of polypharmacy that is unique among neurological disorders, driven by the need to manage primary motor symptoms and nonmotor symptoms of the disease as well as the need to manage complications associated with levodopa (multiple ...
|
read more...
|
$15,000.00
|
The Neurotechnology Industry 2012 Report
8/1/2012 | published by: NeuroInsights, LLC
... comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets. The report includes detailed information on ...
|
read more...
|
$4,500.00
|
Disease and Therapy Review: Parkinson's Disease
6/28/2012 | published by: Timely Data Resources, Inc.
... diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the Parkinson's Disease market, as well as sales of leading drugs and therapies are provided.
|
read more...
|
$995.00
|
|
|
$3,800.00
|
|
|
$2,739.00
|
|
|
$5,700.00
|
|
|
$6,995.00
|
Parkinson's Disease - Pipeline Review, H1 2012
1/23/2012 | published by: Global Markets Direct
... for Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. 'Parkinson's Disease - Pipeline Review, H1 2012' ...
|
read more...
|
$500.00
|
|
|
$1,000.00
|
Parkinson's Disease: World Drug Market 2011-2021
9/26/2011 | published by: Visiongain
... world, submarket, product and national levels to 2021? Through our research and analysis we aim to save you time and help in your decisions. Find out how the drugs Stalevo/Comtess, Sifrol, Azilect and Requip can ...
|
read more...
|
$2,739.00
|
Parkinson's Disease - Pipeline Review, Q3 2011
7/31/2011 | published by: Global Markets Direct
... for Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. 'Parkinson's Disease - Pipeline Review, Q3 2011' ...
|
read more...
|
$500.00
|
|
|
$1,000.00
|
|
|
$750.00
|
Parkinson Disease Therapy Area Pipeline Report
3/14/2011 | published by: Life Science Analytics (LSA)
... as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, ...
|
read more...
|
$1,495.00
|
|
|
$600.00
|
|
|
$500.00
|
|